- Home
- BETR vs CBIO Comparison
BETR vs CBIO Comparison
Compare BETR & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- CBIO
- Stock Information
- Founded
- BETR 2014
- CBIO 2003
- Country
- BETR United States
- CBIO United States
- Employees
- BETR N/A
- CBIO N/A
- Industry
- BETR Finance: Consumer Services
- CBIO
- Sector
- BETR Finance
- CBIO
- Exchange
- BETR Nasdaq
- CBIO Nasdaq
- Market Cap
- BETR 203.4M
- CBIO 173.5M
- IPO Year
- BETR N/A
- CBIO N/A
- Fundamental
- Price
- BETR $25.55
- CBIO $12.50
- Analyst Decision
- BETR
- CBIO Strong Buy
- Analyst Count
- BETR 0
- CBIO 5
- Target Price
- BETR N/A
- CBIO $25.60
- AVG Volume (30 Days)
- BETR 71.8K
- CBIO 88.8K
- Earning Date
- BETR 11-12-2025
- CBIO 07-31-2025
- Dividend Yield
- BETR N/A
- CBIO N/A
- EPS Growth
- BETR N/A
- CBIO N/A
- EPS
- BETR N/A
- CBIO N/A
- Revenue
- BETR $130,672,000.00
- CBIO N/A
- Revenue This Year
- BETR $55.38
- CBIO N/A
- Revenue Next Year
- BETR $71.18
- CBIO N/A
- P/E Ratio
- BETR N/A
- CBIO N/A
- Revenue Growth
- BETR 69.42
- CBIO N/A
- 52 Week Low
- BETR $7.71
- CBIO $10.83
- 52 Week High
- BETR $27.29
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- BETR 55.70
- CBIO 42.36
- Support Level
- BETR N/A
- CBIO $12.09
- Resistance Level
- BETR $25.37
- CBIO $14.50
- Average True Range (ATR)
- BETR 1.34
- CBIO 0.87
- MACD
- BETR -0.81
- CBIO -0.16
- Stochastic Oscillator
- BETR 93.62
- CBIO 16.43
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.